Objective: The objective of this survey was to study the association between circulating proinsulin level and the severity of coronary atherosclerosis. Methods: The study population consisted of 1,039 consecutive patients (775 males and 264 females) who underwent coronary angiography for suspected or known coronary atherosclerosis. The patients’ anthropometric and plasma measurements including body mass index, blood pressure, blood lipid, blood glucose, and proinsulin level were performed. The severity of coronary atherosclerosis was defined by the Gensini’s score system. Results: When proinsulin level was examined as a categorical variable classified by quartile values, subjects with a high proinsulin level had significantly higher values of Gensini’s score than those with a low proinsulin level (p = 0.000). The Spearman correlation analysis suggests that the Gensini’s score was significantly correlated with proinsulin level (r = –0.177, p = 0.000). Multiple stepwise linear regression analysis demonstrated that glucose (β= 0.136, p = 0.000), age (β= 0.189, p = 0.000), proinsulin (β= 0.135, p=0.000), SBP (mm Hg) (β= –0.061, p = 0.043), fasting low-density lipoprotein cholesterol (mmol/l) (β= 0.141, p = 0.003), and total cholesterol (β= –0.105, p = 0.029) are significantly independently associated with the Gensini’s score. Conclusions: Proinsulin is a strong and statistically highly significant pre- dictor of coronary atherosclerosis independent of the other major risk factors including age, body mass index, blood pressure, fasting blood glucose, and blood lipid. The exact mechanisms need further study.

1.
Davies MJ, Rayman G, Gray IP, Day JL, Hales CN: Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med 1993;10:313–320.
2.
Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698–702.
3.
Jenssen T: The many faces of proinsulin. Scand J Clin Lab Invest 2006;66:5–6.
4.
Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey Smith G; aaerphilly Study: Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002;45:327–336.
5.
Zethelius B, Byberg L, Hales CN, Lithell H, Berne C: Proinsulin is an independent predictor of coronary heart disease: Report from a 27-year follow-up study. Circulation 2002;105:2153–2158.
6.
Zethelius B, Lithell H, Hales CN, Berne C: Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia 2005;48:862–867.
7.
Lindahl B, Dinesen B, Eliasson M, Roder M, Jansson JH, Huhtasaari F, Hallmans G: High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48:1197–1202.
8.
Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B: High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000;31:2936–2941.
9.
Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity–clinical research center study. J Clin Endocrinol Metab 1995;80:1399–1406.
10.
Yudkin JS, Denver AE, Mohamed-Ali V, Ramaiya KL, Nagi DK, Goubet S, McLarty DG, Swai A: The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence. A study of two ethnic groups. Diabetes Care 1997;20:1093–1100.
11.
Judkins MP: A percutaneous transfemoral technique. Radiology 1967;89:815–821.
12.
Gensini GG: A more meaningful scoring system for determinating the severity of coronary heart disease. Am J Cardiol 1983;51:606.
13.
Davidson HW, Rhodes CJ, Hutton JC: Interaorgenellar Ca and pH control proinsulin cleavage in the pancreatic B-cell via two site-specific endopeptidases. Nature 1988;333:93–96.
14.
Rhodes CJ, Alarcon C: What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin processing mechanism. Diabetes 1994;43:511–517.
15.
Roder ME, Porte D Jr, Schwartz RS, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998;83:604–608.
16.
Oh JY, Barrett-Connor E, Wedick NM: Sex differences in the association between proinsulin and intact insulin with coronary heart disease in Nondiabetic older adults. The Rancho Bernardo Study. Circulation 2002;105:1311–1316.
17.
Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH: Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15:666–692.
18.
Rautaharju PM: Use and abuse of electrocardiographic classification systems in epidemiologic studies. Eur J Cardiol 1978;8:155–171.
19.
Uusitupa M, Pyorala K, Raunio H, Rissanen V, Lampainen E: Sensitivity and specificity of Minnesota Code Q-QS abnormalities in the diagnosis of myocardial infarction verified at autopsy. Am Heart J 1983;106(pt 1): 753–757.
20.
Mohamed-Ali V, Gould MM, Gillies S, Goubet S, Yudkin JS, Haines AP: Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects – evidence against a modulating role for insulin. Diabetologia 1995;38:1110–1116.
21.
Yudkin JS: Circulating proinsulin-like molecules. J Diabetes Complications 1993;7:113–123.
22.
Nordt TK, Schneider DJ, Sobel BE: Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation 1994;89:321–330.
23.
Festa A, D’Agostino R, Mykkänen L, et al: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999;19:562–568.
24.
Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792–1801.
25.
Lindahl B, Dinesen B, Eliasson M, et al: High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48:1197–1202.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.